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ABSTRACT 
 
 
We describe a microfluidic platform for solid phase screening using extremely small quantities of raw 
materials. Based on our previous set-up for solubility measurement that generates saturated solutions 
directly from powder, the platform requires no solution in excess of that used for the droplet-
crystallization experiment. The set-up is compatible with most solvents and molecules without using 
surfactant.  
Using this microfluidic platform, we first measured the solubility of Sulfathiazole in water, isopropanol, 
and acetonitrile. Second, we performed a polymorph screening of Sulfathiazole using as little as 30 mg 
of raw material, for numerous identical cooling crystallization experiments from 80 to 10°C. In the 
experiments presented, we obtained the 3 usual polymorphs of Sulfathiazole. We show that this 
economical approach yields reliable information on the probability of nucleation of a given polymorph, 
useful in pharmaceutical development.  
 
 
 
INTRODUCTION 
 
Polymorphism is the ability of a molecule to exist in more than one crystalline structure. As a result, 
polymorphs have different physicochemical properties that can profoundly influence the 
bioavailability, manufacturability, purification, stability and solid characteristics of an active 
pharmaceutical ingredient (API)1. Thus, discovering a new polymorph can delay or extend marketing, 
as with Zantac2 and Norvir3. This makes polymorph or general solid phase screening of APIs essential4 
5 in pharmaceutical development. The current empirical approach involves screening the crystallization 
parameters such as supersaturation, temperature, solvent composition, impurities, cooling rates and 
hydrodynamics1. However, this is costly in terms of raw materials. For instance, Morissete et al.4  report 
a range of 1–10 mg of drug per experiment. Moreover, as nucleation is stochastic, it requires numerous 
experiments to obtain reliable data6-8, increasing the consumption of raw materials. In an attempt to 
develop methods that use smaller amounts of materials, small-volume experimental devices have 
been proposed. For example, manipulating fluids at submillimeter scale was first proposed for protein 
crystallization with high-throughput robotic techniques9, 10, and was extended to small molecules with 
arrays of microdroplets of identical composition8 and a lab-on-chip approach11. Lab-on-chip or 
microfluidics platforms/devices for crystallization screening have recently received great interest in 
the literature12-14. However, generation and manipulation of super- and saturated solutions is often an 
issue. The usual method involves preparing a stock solution by adding an excess of powder to a given 
volume of solvent at a given temperature. This suspension is stirred for 24 to 48 hours at the desired 
temperature to reach the thermodynamic equilibrium. The suspension is decanted and the 
supernatant is collected and filtered. The experimental difficulty with this protocol is to maintain the 
 temperature constant during all the steps, to avoid unwanted crystallization. Moreover in microfluidics 
experiments, even if the crystallization experiment consumes only a few µL, stock solutions of at least 
hundreds of µL are required.  
Our aim was, therefore, to develop a microfluidics platform for solid phase screening that eliminates 
the stock solution. We started from the set-up we previously developed for solubility measurement 
based on the generation of saturated solutions directly from powder15. There is no need to prepare 
more solution than what is required for the droplet-crystallization experiment, and the set-up is 
compatible with most solvents and molecules without using surfactant.  
In this paper, we describe our microfluidics platform and how it is used to perform a polymorph 
screening of Sulfathiazole in water, isopropanol and acetonitrile using extremely small quantities of 
material, as little as 30 mg, for cooling crystallization experiments from 80 to 10°C. This microfluidics 
approach was used to perform numerous identical experiments yielding consistent data on polymorph 
nucleation. 
 
EXPERIMENTAL SECTION 
 
Testing Molecules 
Sulfathiazole (4-Amino-N-(2-thiazolyl)benzenesulfonamide) was purchased from Fluka Analytical 
(MKBQ0002V, batch 1001670734). Sulfathiazole is known to exhibit five polymorphic forms: I, II, III, IV, 
and V16, 17.  It is generally accepted that relative thermodynamic stabilities follow the order of the 
densities of the structure, i.e., III  IV> II > I. Form I is the most metastable at room temperature; form 
V has only been crystallized from boiling water and is reputedly very unstable, following a fast solution-
mediated-phase transition to form I8. The commercial we purchased is the stable form III as 
determined by X-ray diffraction analysis.  
GPL  Krytox®  fluorinated oils were purchased from Dupont, FMS and FC70 from Hampton Research. 
Solvents are analytical grade. 
 
Microfluidics Set-up 
All the set-ups presented in this paper are PEEK (polyether ether ketone) devices based on HPLC 
techniques (IDEX Health and Science). T-junctions, precolumn filters, shut-off valves, and PFA 
(Perfluoroalkoxy alkane) tubing (1mm ID), which are resistant to many solvents, render the device 
applicable to mineral, organic and biological materials. The solutions are loaded using separate 
syringes and a programmable syringe pump (neMESYS, cetoni GmbH) controls the flow rates of the 
different fluids.  
 
Solubility measurement 
Sulfathiazole solubility was measured for isopropanol, acetonitrile and water at temperatures 
between 20 and 80 °C with the microfluidics set-up and experimental procedure presented 
previously15. This set-up is used to measure in 4 hours, directly from powder (as little as 30mg), a 
temperature solubility curve (5 to 7 points) in a solvent, with approximately 5% error.  
 
On-line preparation of saturated solutions without pre-knowledge of solubility 
To overcome the risk of unwanted crystallization during handling and save materials, we have 
developed a microfluidics technique of extraction inspired from the set-up we use an extraction set-
up where the solvent flows through a powder bed blocked by a filter. In practice, 30mg of powder is 
placed in a 1mm inner diameter (ID) tube connected to a precolumn filter of 0.5µm (point a on figs.1 
and S1). At the outlet of the filter, due to the dissolution of the powder the solution is at saturation. 
 
Plug factory: generation of saturated droplets 
Droplets are generated by cross-flowing in a T-junction (point b on fig.1). The main channel contains 
the continuous phase, an inert fluorinated oil, and the perpendicular channel contains the dispersed 
 phase, the saturated solution coming from the extraction zone (point b on figs.1 and S1).  The syringe 
pumps control all the flows. Different fluorinated oils were tested (see Table S1), their viscosity varying 
by 2 orders of magnitude with roughly the same interfacial energy with water (almost the same 
chemical composition, except for FMS which contains fluoromethylsiloxan groups) and the same 
solvent compatibility. The most viscous, GPL106 Kryptox®, was selected because it permits good 
droplet stability (no coalescence – note that our set-up involves no surfactant) with temperature 
ranging from 5 to 80°C. To maintain the desired temperature in the generation module, all components 
were placed in an incubator allowing temperature control from room temperature to 80°C18(points a 
and b on figs.1 and S1). 
 
Droplet storage: generation of supersaturation, droplet Incubation and observation module 
Once saturated droplets are generated at a given temperature, tubes are sealed and stored in a water 
incubator (point d on figs.1 and S1) allowing temperature control from 5 to 80°C19. Solutions are 
generated at different concentrations by switching from one outlet tube to another via a manual shut-
off valve (point c on figs.1 and S1). This switch system is placed in an incubator at the same 
temperature as the plug factory to avoid unwanted crystallization during the passage between 
incubator 1 and 2 (fig.1). In all tubes, the concentration is the solubility at the temperature of 
generation (extraction). Then supersaturation is generated by applying a temperature variation profile 
to the droplet incubator.  Time-sequence observation of droplets is carried out using a digital camera 
with various zooms (Opto GmbH) attached to a XYZ motorized arm19.  
 
Bubble killer 
In our preliminary experiments, we noted the presence of bubbles at the filter outlet (point a on fig.1). 
These bubbles are due to solvent cavitationin the filter producing local depressions that trigger solvent 
evaporation. These solvent bubbles cause instabilities in the droplet generation (point b on fig.1). By 
moving in the P-T solvent phase diagram we compensate for these depressions by increasing pressure 
at the filter outlet so that solvent evaporation no longer occurs. Pressure is increased at constant flow 
rate by adding load losses downstream of the circuit. Here, adding 1m of 500µm ID tube at the output 
of the microfluidics set-up (point e on figs.1 and S1), makes it possible to multiply by approximately 3 
the pressure at the outlet of the filter (according to the Poiseuille law) and kills bubbles. 
 
Figure 1: Microfluidics set-up. (a) Microfluidics extraction, (b) Plug factory, (c) Thermostatted manual 
valve, (d) Droplet storage and (e) Bubble killer 
 
Crystallization Procedure for solid form screening 
To test our microfluidics platform for solid phase screening using extremely small quantities, saturated 
droplets generated at 3 different temperatures (45, 55 and 70°C) are stored in 3 different sealed tubes 
at 80°C. The 3 solutions are at 3 different concentrations corresponding to solubilities at 45, 55 and 
70°C (tables 1 and S2). Then the storage temperature is cooled to 10°C in steps of 5°C every 5 hours. 
Pictures of each droplet are taken automatically every 15 minutes to determine the nucleation 
temperature and observe possible transformations such as new nucleation events, solution-mediated-
phase transition or crystal habit modification. 
 
  
Characterization of Solids 
In-situ Raman analysis 
Sulfathiazole crystals are analyzed in situ at the end of the experiment using a Kaiser RXN1 Raman 
microscope system. Measurements are made at room temperature using a 785-nm laser at 10% power, 
with an exposure time of 5s and repeated 5 times. Tubes from the droplet storage zone are placed on 
the stage of the microscope and observed with a 10X objective lens. Droplets containing crystals are 
analyzed: the procedure is first, acquisition of a reference spectrum of a droplet containing solvent 
and Sulfathiazole in solution and second, acquisition of a droplet containing a crystal. This procedure 
allows us to identify the peaks that correspond to the Sulfathiazole crystal and compare them to 
reference spectra of sulfathiazole20, 21 to identify polymorphs. 
 
X-Ray diffraction analysis 
In addition to Raman analysis, X-Ray diffraction (XRD) analyses were performed using an XRD device 
mounted on a Cu rotating anode, Rigaku RU 200BH, with a 2D MAR 345 detector. Crystals were 
harvested from the PFA tubing using the procedure developed by Gerard et al.19 and transferred in 
capillaries of 0.3 or 0.7 mm ID for XRD analysis. An exposure time of 360s was used.  
 
RESULTS AND DISCUSSION 
 
Solubility 
Solubilities of Sulfathiazole (Form III) in water, isopropanol, and acetonitrile are shown in figure 2. To 
ensure that no phase transition occurs during the experiment, Raman spectra of the powder bed were 
taken before and after all experiments. Van't Hoff plot (fig.S2) and dissolution enthalpy values are  
given in  Supplementary Information (table S3). 
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Figure 2: Solubilities of Sulfathiazole form III in water, isopropanol, and acetonitrile. The curves are 
exponential fits to our measurements.  
 
Sulfathiazole solid form screening  
Because acetonitrile and isopropanol are better solvents than water, Sulfathiazole solubilities were 
greater in these solvents. However, nucleation was more difficult in these solvents (figs. S3 and S4). 
 This result is in disagreement with the empirical rule that the higher the solubility, the easier 
nucleation22. In the literature, this phenomenon has already been observed, in particular by Anderson 
et al23 who showed that nucleation kinetics in water are faster than in 1-propanol, ammonia and that 
there is no nucleation in nitromethane, although solubilities follow the reverse order. The difficulty of 
nucleation may therefore come from the solvent-solute association, as previously described by Gu et 
al24 for the polymorphism of Sulfamerazine. Due to low nucleation of Sulfathiazole in isopropanol and 
acetonitrile, we discuss in the following only experiments in water. 
 
Droplet observation and solid phase characterization by in-situ Raman spectroscopy 
We generated saturated droplets at 3 different temperatures (45, 55 and 70°C), corresponding to 3 
initial concentrations Ci (Table 1). These droplets are stored in 3 different sealed tubes at 80°C. After 
cooling from 80°C to 10°C, we have a set of about 5000 images at the end of the crystallization 
experiment. Figure 3 shows micrographs of representative droplets for each Ci. The different crystal 
habits obtained (fig.4), correspond to different polymorphs as confirmed by Raman and XRD 
characterization. From the time-sequence images produced during the experiment, we obtained 
nucleation statistics as plotted in figure 5 for each Ci. 
 
Temperature (°C) Ci (mg/mL) 
45 1.56 
55 2.64 
70 5.87 
Table 1: Concentration of Sulfathiazole in water at the different temperatures of preparation (Ci). 
 
 
Figure 3: Micrographs of droplets at the end of the experiment of crystallization of Sulfathiazole in 
water (a) droplets generated at 70°C (Ci=5.87mg/mL), (b) droplets generated at 55°C (Ci=2.64mg/mL), 
(c) droplets generated at 45°C (Ci=1.56mg/mL). 
 
(a) 
(b) 
(c) 
    
Figure 4: Different crystal habits observed for crystallization of Sulfathiazole in water in 1mm droplets 
(a) form II, (b) form III and (c) form IV. 
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Figure 5: Percentage of nucleated droplets during Sulfathiazole the cooling crystallization experiment 
in water. 
 
Crystals nucleated in about 60 droplets out of 90. They were all analyzed by Raman spectroscopy and 
typical spectra obtained are presented in figure 6. The sequential image acquisition allows us to 
confirm that there is not a second nucleation event nor a solution-mediated-phase transition in any 
droplet. This confirms that small volumes "freeze" (stabilize) the phase nucleated, as previously 
observed25, 26.   Identification of the 3 polymorphs, II – III and IV, was confirmed by XRD on 3 samples, 
in agreement with the data from the Cambridge Structural Database files Suthaz, Suthaz02 and 
Suthaz04 respectively (https://www.ccdc.cam.ac.uk/). 
 
(c) (a) (b) 
  
Figure 6: Different Raman spectra observed for crystals of Sulfathiazole polymorphs in water in 1mm 
droplets. The bottom curve corresponds to a reference spectrum of a supersaturated droplet without 
crystals. 
 
The great advantage of this microfluidics approach lies in enabling numerous (here 30) identical 
experiments to be performed, thereby ensuring consistent data on polymorph nucleation. The 
percentages of different polymorphs crystallized at the end of the experiments are summarized in 
table 2. Starting from a powder of form III, all the Ci yield polymorphs of forms II, III and IV. Ci of 2.64 
and 5.87mg/mL lead mainly to form IV, i.e. in 69% of the droplets. A Ci of 1.56mg/mL leads only to 20% 
of nucleated droplets, a few droplets for each form. This highlight the advantage of generating a large 
number of identical crystallization experiments, notably due to stochasticity of nucleation.  
 
 Ci=1.56 mg/mL Ci=2.64 mg/mL Ci=5.87 mg/mL 
% Form II (# of crystallized droplets) 40 (2) 11.6 (3) 19.2 (5) 
% Form III (# of crystallized droplets) 20 (1) 19.2 (5) 11.6 (3) 
% Form IV (# of crystallized droplets) 40 (2) 69.2 (18) 69.2 (18) 
% of crystallized droplets 19.2 100 100 
Table 2: percentages of different polymorphs crystallized at the end of the experiment 
 
Figure 7 summarizes the data collected during the cooling crystallization experiment. In this screening, 
using 30mg of API, and only one cooling profile gives the 3 usual polymorphs of Sulfathiazole, forms II, 
III and IV. This information on the probability of nucleation of a given polymorph is useful in 
pharmaceutical development. 
 
 
  
 
Figure 7: Graphical summary of polymorphs obtained during cooling crystallization, to 10°C by steps 
of 5°C every 5 hours, of Sulfathiazole in water. 
 
CONCLUSIONS 
 
We present in this paper the development of a microfluidics platform for solid phase screening using 
extremely small quantities of raw materials. This microfluidics platform is based on our previous set-
up for solubility measurement generating saturated solutions directly from powder. No solution in 
excess of that used for the droplet-crystallization experiment is required and the set-up is compatible 
with most solvents and molecules without using surfactant.  
Using this microfluidics platform, we first measured the solubility of Sulfathiazole in water, isopropanol, 
and acetonitrile. Second, we performed a polymorph screening of Sulfathiazole using extremely small 
quantities of material, as little as 30 mg, for numerous identical cooling crystallization experiments 
from 80 to 10°C. In the experiments presented, we obtained the 3 usual polymorphs of Sulfathiazole. 
We show that this approach yields reliable information on the probability of nucleation of a given 
polymorph, useful in pharmaceutical development. Further studies could usefully explore different 
cooling policies that may influence the probability of nucleation of different polymorphs. 
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Interfacial tensions between oil and water were measured by the pendant drop method 
using Dataphysics OCA 20 (Optical Contact Angle) setup. 
 
Name Density Viscosity at 
20°C (cSt) 
Oil/water interfacial 
tension at 20°C (mN/m) 
FMSa 1,25 300-350 41 (0.5) 
FC70a 1,94 12 (at 25°C) 53.7 (0.5) 
GPL103 b 1.92 82 56.7 (0.2) 
GPL105b 1.93 522 58.8 (0.1) 
GPL106 b 1.94 822 58.3 (0.2) 
a: from Hampton Research and b: from DuPont 
Table S1 : Typical properties of FMS, FC70 Fluorinert® and Krytox® fluorinated 
oils  
 
 
Figure S1: Microfluidics set-up. (a) Microfluidics extraction, (b) Plug factory, (c) Thermostatted 
manual valve, (d) Droplet storage and (e) Bubble killer 
 
Temperature (°C) Concentration 
(mg/mL of water) 
Concentration 
(mg/mL of isopropanol) 
Concentration 
(mg/mL of acetonitrile) 
45 1.56 3.20 12.30 
55 2.64 4.46 17.22 
70 5.87 7.35 28.52 
Table S2: Concentration of sulfathiazole in water, isopropanol and acetonitrile at the different 
preparation temperatures 
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Figure S2 : van't Hoff plot of sulfathiazole form III solubilities in different solvents 
 
Solvent ΔHd (kJ/mol) 
acetonitrile 27.8 
isopropanol 27.5 
water 43.3 
Table S3: Dissolution Enthalpies in different solvents from van't Hoff plot of 
sulfathiazole form III solubilities (fig.S1)  
 
 
 
  
 
Figure S3: Graphical summary of polymorphs obtained during cooling crystallization, to 10°C by steps 
of 5°C every 5 hours, of Sulfathiazole in isopropanol. 
 
 
 
  
 
Figure S4: Graphical summary of polymorphs obtained during cooling crystallization, to 10°C by steps 
of 5°C every 5 hours, of Sulfathiazole in acetonitrile. 
 
 
 
 
 
 
